Retention rates of levetiraceram in Chinese children and adolescents with epilepsy

BackgroundLevetiracetam (Lev) is a new antiepileptic drugs, proved to be effective and tolerance in regulatory trials, but these controlled trials do not always predict how useful a drug will be in day to day clinical practice, Retention rates can provide a better indication of efficacy and tolerability in everyday use.MethodsTotally 124 patients with more than 3 months disease course were enrolled in the study from June 2007 to December 2007. The LEV dose ranged from 10 to 60 mg/kg per day. Follow up visit were performed at 6 months, 12 months, 24 months and 36 months, and treatment effects, adverse effects were recorded.ResultsThe LEV retention rates at 6, 12, 24, and 36 months were 93.5% (116/124), 84.7% (105/124), 65.3% (81/124), and 58.9% (73/124), respectively. The predominant causes of withdrawal were lack of efficacy (62.7%) and serious adverse effects (17.6%). In addition, 48.6% (51/105), 60.5% (49/81) and 72.6% (53/73) patients were seizure-free for 12 months, 24 months and 36 months, respectively. In this study, 75 (60.5%) patients experienced at least one side effect. The most common side effects observed were irritability 38.7% (29/75), somnolence 17.3% (13/75), learning disability 16.0% (12/75), anorexia 17.3% (13/75), somnipathy 13.3% (10/75), and abnormal behavior 13.3% (10/75).ConclusionsOur study revealed the high retention rate of LEV in Chinese children and adolescents with epilepsy.